The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma-Reference-Cited by-同舟云学术

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Published:2021-11-18 Issue:12 Volume:5 Page:e666
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Delgado Julio,Papadouli Irene,Sarac Sinan B.,Moreau Alexandre,Hovgaard Doris,Gisselbrecht Christian,Enzmann Harald,Pignatti Francesco

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference23 articles.

1. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.;Sant;Blood,2010

2. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study.;De Angelis;Lancet Oncol,2014

3. p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell.;Tessoulin;Blood Rev,2017

4. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma.;Rosenthal;Blood Rev,2017

5. A predictive model for aggressive non-Hodgkin’s lymphoma.;N Engl J Med,1993

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project;eJHaem;2024-02-23

2. Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze;HemaSphere;2024-01

3. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study;Blood;2023-12-28

4. Second Line Treatment of DLBCL: Evolution of Options;Seminars in Hematology;2023-12

5. Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas;Haematologica;2023-06-01